报告题目：Engineered nanoparticles for cancer imaging and therapy
报 告 人：杨涛 博士（Innovation center of nanomedicine）
Tao Yang obtained his PhD in Pharmaceutical Science from Soochow University in June 2018. His ph.D work in Soochow University was focusing on developing protein nanoreactor for precise cancer imaging-guided phototherapy, which is highly potential for the application in precision medicine and personalized treatment. Currently, as a research scientist at iCONM, he focused primarily on the development of ligand installed PEGylated antibody across BBB for activable brain tumor immunotherapy. So far, Dr. Yang has published over 15 peer-viewed papers in high-class journals in the field of nanomedicine, including published as the first author in Advanced Materials (IF 25.8), ACS Nano (IF 13.9), Theranostics (IF 8.7), Biomaterials (IF 10.3) and so on.
Clinically potential proteins such as human serum albumin are utilized as single-molecule nanoreactors for fabrication of size-tunable inorganic nanoparticles or drug-loaded nanoparticles with well-defined nanostructure. The fabrication is accomplished within hollow protein nanocages through biomineralization-mediated controlled growth. These cancer-targeted protein nanoparticles are able to achieve multimodal imaging with both ultrasensitivity and spatial resolution, as well as potent cancer therapy.